• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia

tetano

Editor, Senior Moderator
Cell


. 2021 Apr 24;S0092-8674(21)00536-5.
doi: 10.1016/j.cell.2021.04.033. Online ahead of print.
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia


Daniel Asarnow[SUP] 1 [/SUP], Bei Wang[SUP] 2 [/SUP], Wen-Hsin Lee[SUP] 2 [/SUP], Yuanyu Hu[SUP] 2 [/SUP], Ching-Wen Huang[SUP] 2 [/SUP], Bryan Faust[SUP] 1 [/SUP], Patricia Miang Lon Ng[SUP] 2 [/SUP], Eve Zi Xian Ngoh[SUP] 2 [/SUP], Markus Bohn[SUP] 3 [/SUP], David Bulkley[SUP] 1 [/SUP], Andr?s Pizzorno[SUP] 4 [/SUP], Beatrice Ary[SUP] 3 [/SUP], Hwee Ching Tan[SUP] 2 [/SUP], Chia Yin Lee[SUP] 2 [/SUP], Rabiatul Adawiyah Minhat[SUP] 2 [/SUP], Olivier Terrier[SUP] 4 [/SUP], Mun Kuen Soh[SUP] 2 [/SUP], Frannie Jiuyi Teo[SUP] 2 [/SUP], Yvonne Yee Chin Yeap[SUP] 2 [/SUP], Shirley Gek Kheng Seah[SUP] 5 [/SUP], Conrad En Zuo Chan[SUP] 5 [/SUP], Emily Connelly[SUP] 6 [/SUP], Nicholas J Young[SUP] 6 [/SUP], Sebastian Maurer-Stroh[SUP] 7 [/SUP], Laurent Renia[SUP] 8 [/SUP], Brendon John Hanson[SUP] 5 [/SUP], Manuel Rosa-Calatrava[SUP] 9 [/SUP], Aashish Manglik[SUP] 10 [/SUP], Yifan Cheng[SUP] 11 [/SUP], Charles S Craik[SUP] 12 [/SUP], Cheng-I Wang[SUP] 13 [/SUP]



Affiliations
Free PMC article

Abstract

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by binding of the viral Spike protein to host receptor angiotensin-converting enzyme 2 (ACE2), followed by fusion of viral and host membranes. Although antibodies that block this interaction are in emergency use as early coronavirus disease 2019 (COVID-19) therapies, the precise determinants of neutralization potency remain unknown. We discovered a series of antibodies that potently block ACE2 binding but exhibit divergent neutralization efficacy against the live virus. Strikingly, these neutralizing antibodies can inhibit or enhance Spike-mediated membrane fusion and formation of syncytia, which are associated with chronic tissue damage in individuals with COVID-19. As revealed by cryoelectron microscopy, multiple structures of Spike-antibody complexes have distinct binding modes that not only block ACE2 binding but also alter the Spike protein conformational cycle triggered by ACE2 binding. We show that stabilization of different Spike conformations leads to modulation of Spike-mediated membrane fusion with profound implications for COVID-19 pathology and immunity.

Keywords: COVID-19; SARS-CoV; SARS-CoV-2; Spike protein; coronavirus; phage display; receptor binding domain (RBD); recombinant monoclonal antibody; syncytia.
 
Back
Top Bottom